Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection

K Muzammil, MH Hooshiar, S Varmazyar… - Microbial Cell …, 2024 - Springer
Cellular lipid membranes serve as the primary barrier preventing viral infection of the host
cell and provide viruses with a critical initial point of contact. Occasionally, viruses can utilize …

Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK

Z Iqbal, JH Ho, S Adam, M France, A Syed, D Neely… - Atherosclerosis, 2020 - Elsevier
The emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) which causes Coronavirus Disease 2019 (COVID-19) has resulted in a pandemic. SARS …

[PDF][PDF] Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic

N Katsiki, M Banach, D Mikhailidis - Archives of Medical Science, 2020 - termedia.pl
Lipid-lowering therapy and renin-angiotensin- aldosterone system inhibitors in the era of the
COVID-19 pandemic Page 1 Creative Commons licenses: This is an Open Access article …

Insight into the Evolving Role of PCSK9

M Maligłówka, M Kosowski, M Hachuła, M Cyrnek… - Metabolites, 2022 - mdpi.com
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the last discovered member of the
family of proprotein convertases (PCs), mainly synthetized in hepatic cells. This serine …

PCSK9 inhibition: From effectiveness to cost-effectiveness

I Mercep, D Strikic, P Hrabac, I Pecin… - Frontiers in …, 2024 - frontiersin.org
Dyslipidaemia is a complex disorder characterised by abnormal lipid levels in the blood,
including cholesterol and triglycerides, and plays an important role in the development of …

Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels–experimental and clinical approaches with lipid-lowering agents

C Macchi, M Banach, A Corsini… - European Journal of …, 2019 - academic.oup.com
Regulation of pro-protein convertase subtilisin/kexin type 9 (PCSK9) by drugs has led to the
development of a still small number of agents with powerful activity on low-density …

[PDF][PDF] Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk

A Vuorio, GF Watts, PT Kovanen - J Intern Med, 2020 - screenprofh.com
From the 1Mehiläinen Airport Health Centre, Vantaa, Finland; 2University of Helsinki,
Department of Forensic Medicine, Helsinki, Finland; 3School of Medicine, Faculty of …

Reduced plasma PCSK 9 response in patients with bacteraemia is associated with mortality

J Rannikko, D Jacome Sanz, Z Ortutay… - Journal of Internal …, 2019 - Wiley Online Library
Background The proprotein convertase subtilisin/kexin type 9 (PCSK 9) enzyme controls
blood cholesterol levels by downregulating the expression of the low‐density lipoprotein …

Small molecule inhibitor of ATPase activity of HSP70 as a broad-spectrum inhibitor against flavivirus infections

J Yang, Y Xu, Y Yan, W Li, L Zhao, Q Dai… - ACS infectious …, 2020 - ACS Publications
Flaviviruses including Zika virus, Dengue virus, Japanese Encephalitis virus, and Yellow
Fever virus cause heavy burdens to public health around the world. No specific antiviral …

Altered lipid profile is a risk factor for the poor progression of COVID-19: from two retrospective cohorts

H **, J He, C Dong, B Li, Z Ma, B Li… - Frontiers in Cellular …, 2021 - frontiersin.org
Background The coronavirus disease 2019 (COVID-19) pandemic has spread worldwide.
However, the impact of baseline lipid profile on clinical endpoints in COVID-19 and the …